


VACCINOLOGY

PRINCIPLES AND PRACTICE

EDITED BY

W. John W. Morrow | Nadeem A. Sheikh
Clint S. Schmidt | D. Huw Davies



 WILEY-BLACKWELL

Contents

[Cover](#)

[Title Page](#)

[Copyright](#)

[List of Contributors](#)

[Preface](#)

[Part 1: Introduction](#)

[Chapter 1: Concept and Scope of Modern Vaccines](#)

[Introduction](#)

[Triumphs and limitations of current vaccination](#)

[Modern approaches that impact vaccine design](#)

[A return to attenuated organisms?](#)

[Improve existing vaccines and vaccine uptake](#)

[Hurdles and challenges for the future](#)

[Part 2: Principles of Vaccine Design](#)

[Chapter 2: Strategies to Stimulate Innate Immunity for Designing Effective Vaccine](#)

Adjuvants

Principles of vaccine design: stimulation of innate immunity

Innate immune stimulators

Practical applications for adjuvants

Summary

Acknowledgements

Chapter 3: Antigen Processing and Presentation by MHC Class I, II, and Nonclassical Molecules

MHC class I and II structure

MHC molecule assembly

Peptide generation

Cross- and criss-cross presentation

Summary

Acknowledgments

Chapter 4: Understanding the Mucosal Immune System for Better Mucosal Vaccine Design

Introduction

Anatomy of the mucosal immune system

Players of the mucosal immune system

Mucosal vaccines: current strategies and ongoing challenges

Final word

Chapter 5: Immunologic Memory: T Cells in Humans

Introduction

Generation of memory T cells

Induction of T-cell memory with a vaccine

Concluding remarks

Acknowledgments

Chapter 6: Immunologic Memory: B Cells

Introduction

Human evaluation of B-cell vaccine responses

Variability in antibody maintenance is dependent on the type of vaccine

Primary B-cell immune response

Secondary B-cell immune responses

Factors important for long-lived plasma cell generation

Heterogeneity of the circulating newly formed ASCs

Models of long-lived plasma cells maintenance

Heterogeneity of human memory B-cell subsets

Measuring memory B-cell responses to vaccines

Antibody maintenance is dependent on the age of the host

Location of memory B cells and plasma cells may play a role in protection

Biomarkers of long-lived humoral immunity during vaccine priming

Chapter 7: Utility of Mouse Models in Vaccine Design and Development

Why the Mouse?

Why mouse models for vaccine development

Experimental mouse models of human pathogens

Mice as models for lethal human pathogens

Concluding remarks

Chapter 8: Utility of Nonhuman Primate Models for Vaccines

Introduction

SIVs and SIV/HIV hybrid viruses (SHIV) used for vaccine studies

SIVmac group: SIVmac251, SIVmac239, and vaccine challenge viruses

SIVB670/H4/H9 group and vaccine challenge viruses

SHIV group

HIV-1 infection of pig-tailed macaques

Challenge routes of infection for testing vaccine efficacy

AIDS vaccine models

Acknowledgments

Part 3: Antigen Discovery

Chapter 9: Sequence-Based Computational Approaches to Vaccine

Discovery and Design

Introduction

Designing vaccines based on alignments

Designing vaccines using epitope prediction

Conclusions

Chapter 10: Antigen Discovery for Vaccines Using High-throughput Proteomic Screening Technologies

Introduction

"Synthetic" proteomes

HT antibody screening

T-cell screening platforms

Strategies for identification of protective antigens

Translation of HT screening into protective vaccines

Future challenges

Chapter 11: Phage Libraries

Introduction

Peptide mimotopes

Infectious disease mimotopes

Cancer mimotopes

Other mimotope applications

Phage vaccines

Antigen discovery and epitope mapping

Conclusion and future direction

Part 4: Antigen Engineering

Chapter 12: Attenuated Bacterial Vaccines

Introduction

Live attenuated, killed, or subunit vaccines?

Existing live attenuated vaccines

Rationally attenuated live vaccines

Auxotrophs

Regulatory mutants

Immune responses to live attenuated vaccines

Safety of live attenuated vaccines

Live attenuated vaccines as vaccine carriers

Conclusions

Chapter 13: Virus-like Particles as Antigen Scaffolds

Virus-like particles, a new class of vaccines

Properties of VLPs that promote immune responses

Commercial VLP-based vaccines

Exploiting VLPs as platform for antigenic display of heterologous target molecules

Recombinant VLPs

Display of target antigens by chemical conjugation

Recombinant virosomes

Synthetic multivalent platforms

Conclusions

Acknowledgments

Chapter 14: Recombinant MVA vaccines: Optimization, Preclinical, and Product Development

Aims of the chapter

Introduction to MVA

MVA molecular biology and replication

Construction and use of recombinant MVA

rMVA development

Summary

Acknowledgments

Chapter 15: Recombinant Adenoviruses for Vaccination

Adenovirus vectors for vaccination: advantages and problems

Basic concepts of Ad vaccination

Specific examples for Ad-based vaccination

Conclusions and future directions

Chapter 16: Recombinant Avipoxviruses

Introduction

Avipoxvirus phylogeny

Disease control: vaccination and transmission control

Recombinant vector strains

Biosafety and environmental safety

Genome sequences

Promoters

Insertion sites

[Recombination strategies](#)
[Recombinant selection and screening](#)
[Propagation of rFWPV](#)
[Poultry vaccines](#)
[Mammalian vaccines: background and introduction](#)
[Mammalian vaccines: veterinary](#)
[Preclinical and clinical human vaccine trials](#)
[Immune responses induced by avipoxvirus vectors](#)
[Enhanced avipoxvirus vectors](#)
[Acknowledgments](#)

[Chapter 17: Intracellular Facultative Bacterial Vectors for Cancer Immunotherapy](#)

[Patho-biotechnology and the challenge of tumor immunotherapy](#)
[The biology of intracellular bacterial vectors](#)
[Bacille Calmette-Guérin](#)
[Shigella flexneri](#)
[Salmonella enterica](#)
[Listeria monocytogenes](#)
[Discussion](#)

[Chapter 18: Nucleic Acid Vaccination](#)

[Background](#)
[Modifications of genes and gene expression](#)
[Infectious diseases](#)

Cancer

Allergy and autoimmune diseases

Licensed DNA vaccines

Delivery

Production

Chapter 19: Artificial Antigen-presenting Cells: Large Multivalent Immunogens

Introduction

CD8 T-cell activation and memory development

Activation of CD8 T cells for tumor immunotherapy

Artificial APC for ex vivo activation and adoptive transfer of T cells

Artificial APC for in vivo T-cell activation: large multivalent immunogen

Future directions

Acknowledgments

Part 5: Delivery Systems

Chapter 20: Transcutaneous Immunization via Vaccine Patch Delivery System

Introduction

Skin immunology system and TCI mechanism

General TCI principles learned from preclinical studies

Clinical studies involving TCI using early-stage, “wet” patch format

[Technical advances: dry vaccine patch delivery system](#)

[Recent clinical applications with LT dry patches](#)

[Commentary and future direction](#)

[Acknowledgments](#)

[Chapter 21: Needle-free Jet Injection for Vaccine Administration](#)

[Introduction](#)

[Liquid jet injectors](#)

[Solid jet injectors](#)

[Conclusion](#)

[Chapter 22: Oral Vaccines: An Old Need and Some New Possibilities](#)

[Introduction](#)

[Polio vaccine](#)

[Cholera vaccine](#)

[Typhoid vaccine](#)

[Rotavirus vaccine](#)

[Plant-derived vaccines: current status and challenges ahead](#)

[Plant-based vaccine trials](#)

[Acknowledgments](#)

[Chapter 23: Adjuvants: From Serendipity to Rational Discovery](#)

[What are adjuvants and why do we need them?](#)

[Safety safety safety](#)

Mechanisms of adjuvanticity: the target cells

Mechanisms of adjuvanticity: the target molecules

Outlook: what will the adjuvants of the future look like?

Conclusions

Chapter 24: Immunostimulatory Properties of Biodegradable Microparticles

Introduction

Particulate vaccine adjuvants

Combination vaccine adjuvants

How do particulate vaccine adjuvants work?

Chapter 25: Co-administration of Co-stimulatory Moieties

Introduction

Negative regulatory members of the CD28 superfamily

Negative regulatory pathways and enhancement of tumor immunity

Negative pathways and viral infections

Blocking positive co-stimulation signals in autoimmunity

Conclusion

Chapter 26: Toll Receptors in Relation to Adjuvant Effects

Toll-like receptors

[TLR signaling](#)
[TLRs in immunity](#)
[TLR agonists as vaccine adjuvant](#)
[Safety issues and open questions](#)
[Future directions](#)
[Acknowledgments](#)

[Part 6: Regulatory Considerations](#)

[Chapter 27: Regulatory Issues \(FDA and EMA\)](#)

[Vaccines: an overview](#)
[DNA vaccines and monoclonal antibody vaccines](#)
[Herceptin[®]](#)
[Cervarix[®]](#)
[Provenge[®]](#)
[Yervoy[™] \(ipilimumab\)](#)
[Swine flu vaccine](#)
[Use of transgenic animals in vaccine development](#)
[EU licensing system](#)
[US licensing system](#)
[Reforms within the EMA and FDA](#)
[Conclusion](#)
[Acknowledgment](#)

[Part 7: Evaluating Vaccine Efficacy](#)

Chapter 28: Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine

Introduction

Challenges for immune monitoring

Immune monitoring design along the vaccine pipeline

Sample logistics

Current established assays

Complex assays

New technologies

Qualification and validation of immune monitoring assays

Response definition

Summary

Chapter 29: Clinical Development Strategy: Nuts and Bolts

Introduction

Rotavirus

Human papillomavirus

Summary

Acknowledgment

Chapter 30: Current Approaches to Identify and Evaluate Cancer Biomarkers for Patient Stratification

General overview

Breast cancer: developmental risk
Molecular heterogeneity of breast cancer
Prediction of outcome based on
clinicopathological features
Prediction of outcome based on molecular
features and profiling
Prediction of response to therapy
Toward personalized medicine for breast cancer
patients
Omic technologies
Patient modeling based on genomic and
proteomic data
Perspective on biomarkers in personalized
medicine
Acknowledgments

Part 8: Implementing Immunizations/Therapies

Chapter 31: Mass Immunization Strategies

Mass immunization: history and concept
Routine and mass immunization as
complementary strategies
Preventing and responding to emerging
outbreaks
Accelerated disease control
Mass immunization for disease eradication:
example polio eradication

[Mass immunization campaigns: programmatic issues](#)

[Mass immunization: future outlook](#)

[Chapter 32: The Role of Mathematical Models in Vaccine Development and Public Health Decision Making](#)

[Introduction](#)

[Key concepts of infectious disease spread and control](#)

[Cost-effectiveness analysis](#)

[The application of mathematical models at different stages of vaccine development](#)

[Discussion](#)

[Chapter 33: Vaccine Safety](#)

[Overview of post-licensure monitoring](#)

[Overview of methodology and systems used to study vaccine safety](#)

[Clinical vaccine safety research and practice](#)

[Case studies](#)

[Approach to vaccine safety controversies](#)

[Summary](#)

[Index](#)

Vaccinology

Principles and Practice

EDITED BY

W. John W. Morrow, PhD, DSc, FRCPath

Seattle, WA, USA

Nadeem A. Sheikh, PhD

Dendreon Corporation
Seattle, WA, USA

Clint S. Schmidt, PhD

NovaDigm Therapeutics, Inc.
Grand Forks, ND, USA

D. Huw Davies, PhD

University of California at Irvine
Irvine, CA, USA

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2012, ©2012 by Blackwell Publishing Ltd.

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell's publishing program has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office:

John Wiley & Sons, Ltd, The Atrium, Southern Gate,
Chichester, West Sussex, PO19 8SQ, UK

Editorial offices:

9600 Garsington Road, Oxford, OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex, PO19
8SQ, UK

350 Main Street, Malden, MA 02148-5020, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is

designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work.

Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Vaccinology : principles and practice / edited by W. John W. Morrow ... [et al.].
p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-4051-8574-5 (hardback : alk. paper)

I. Morrow, John, 1949-

[DNLM: 1. Vaccines. 2. Drug Design. 3. Vaccination-methods. QW 805]

615.3'72-dc23

2012002555

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

List of Contributors

Murrium Ahmad, PhD

The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK

Sir Roy M. Anderson, FRS, FMedSci

Chair in Infectious Disease Epidemiology
Division of Epidemiology, Public Health and Primary Care,
School of Public Health, London, UK

Antony N. Antoniou, PhD

Senior Research Fellow Department of Infection and Immunity/Centre of Rheumatology, University College London, London, UK

Victor Appay

INSERM UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie (UPMC), Sorbonne Universités, and Hôpital Pitié-Salpêtrière, Paris, France

Carolina Arancibia-Cárcamo, PhD

Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

Helen S. Atkins, BSc, PhD

Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, UK

R. Bruce Aylward, MD, MPH

Assistant Director-General, Polio, Emergencies and Country Collaboration, World Health Organization, Geneva, Switzerland

Lorne A. Babiuk, OC, SOM, PhD, DSc, FRSC

Office of Vice President Research, University of Alberta, Edmonton, Canada

Graham Ball

The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, and CompanDX Ltd, Nottingham, UK

Janine Bilsborough, PhD

Inflammation Research, Amgen, Thousand Oaks, CA, USA

Marie-Claude Boily, PhD

Senior Lecturer in Infectious Disease Ecology
Division of Epidemiology, Public Health and Primary Care,
School of Public Health, London, UK

Diane L. Bolton

Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

Catharine M. Bosio, PhD

Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

Marc Brisson, PhD

Unité de Recherche en Santé des Populations, Centre de Recherche Fonds de la Recherche en Santé du Québec du

Centre Hospitalier affilié Universitaire de Québec, Canada

Victoria Byers

NJM European Economic & Management Consultants Ltd,
Gosforth, Newcastle Upon Tyne, UK

Claudio Carini, MD, PhD

Boston Biotech Clinical Research, Cambridge, MA, USA

Miles W. Carroll, PhD

Microbiology Division, Health Protection Agency, Porton
Down, UK

Darrick Carter, PhD

Protein Advances, Inc., Seattle, WA, and Infectious Disease
Research Institute, Seattle, WA, USA

Bryce Chackerian, PhD

Department of Molecular Genetics and Microbiology,
University of New Mexico School of Medicine, Albuquerque,
NM, USA

Dipshikha Chakravorty, PhD

Department of Microbiology and Cell Biology, Center for
Infectious Disease Research and Biosafety Laboratories,
Indian Institute of Science, Bangalore, India

Robert T. Chen, MD, MA

Division of HIV/AIDS Prevention, National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers
for Disease Control and Prevention (CDC), Atlanta, GA, USA

Zhengrong Cui

Pharmaceutics Division, College of Pharmacy, University of Texas-Austin, Austin, USA

Julie M. Curtsinger, PhD

Department of Laboratory Medicine & Pathology, Center for Immunology, University of Minnesota, Minneapolis, MN, USA

Priyanka Das

Department of Microbiology and Cell Biology, Center for Infectious Disease Research and Biosafety Laboratories, Indian Institute of Science, Bangalore, India

Nelson Cesar Di Paolo, PhD

Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA, USA

Candida Fratazzi, MD

Boston Biotech Clinical Research, Cambridge, MA, USA

Volker Gerds, DVM

Vaccine & Infectious Disease Organization, Saskatoon; Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK, Canada

Jane Gidudu MD, MPH

Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

Gregory M. Glenn

Intercell USA, Inc., Gaithersburg, MD, USA

David B. Guiliano

Division of Infection and Immunity/Centre for Rheumatology,
Windeyer Institute of Medical Science, University College
London, London, UK

Patrick Guirnalda, PhD

Department of Microbiology, University of Pennsylvania,
Philadelphia, PA, USA

Yper Hall, BSc

Microbiology Division, Health Protection Agency, Porton
Down, UK

David L. Heymann, MD, DTM&H

Professor and Chair, Infectious Disease Epidemiology,
London School of Hygiene and Tropical Medicine, London, UK

Maria Candela Iglesias

INSERM UMR S 945, Infections and Immunity, Avenir Group,
Université Pierre et Marie Curie (UPMC), Sorbonne
Universités, and Hôpital Pitié-Salpêtrière, Paris, France

John Iskander, MD, MPH

Office of the Associate Director for Science, Centers for
Disease Control and Prevention (CDC), Atlanta, GA, USA

Camilla Jandus, MD, PhD

Division of Clinical Onco-Immunology, Ludwig Institute for
Cancer Research, Lausanne, Switzerland

Sylvia Janetzki, MD

Zellnet Consulting, Inc., Fort Lee, NJ, USA

Ross M. Kedi, PhD

Department of Immunology, University of Colorado Denver,
Denver, CO, USA

Amit Lahiri

Department of Microbiology and Cell Biology, Center for
Infectious Disease Research and Biosafety Laboratories,
Indian Institute of Science, Bangalore, India

Stephen M. Laidlaw

Department of Virology, Imperial College London Faculty of
Medicine, London, UK

Yvette Latchman, PhD

The Puget Sound Blood Center, Seattle, WA, USA

Ed C. Lavelle, PhD

Adjuvant Research Group, School of Biochemistry and
Immunology, Trinity Biomedical Sciences Institute, Trinity
College, Dublin, Ireland

Stephanie Laversin

The John van Geest Cancer Research Centre, School of
Science and Technology, Nottingham Trent University,
Nottingham, UK

F. Eun-Hyung Lee, MD

Emory University Department of Medicine, Division of
Pulmonary, Allergy, and Critical Care Medicine, Atlanta, GA,
USA

Izabela Lenart

Division of Infection and Immunity/Centre for Rheumatology,
Windeyer Institute of Medical Science, University College

London, London, UK

André Lieber, MD, PhD

Department of Medicine, Division of Medical Genetics, and
Department of Pathology, University of Washington, Seattle,
WA, USA

Margaret A. Liu, MD

ProTherImmune, Lafayette, CA, USA

Amit A. Lugade, PhD

Department of Immunology, Roswell Park Cancer Institute,
Buffalo, NY, USA

Megan MacLeod, PhD

Integrated Department of Immunology, Howard Hughes
Medical Institute, National Jewish Health, Denver, CO, USA

Philippa Marrack, PhD

Integrated Department of Immunology, Howard Hughes
Medical Institute, National Jewish Health, Denver, CO, USA

Preston A. Marx Jr, PhD

Tulane National Primate Research Center, Tulane University,
Covington, LA, USA

Matthew F. Mescher, PhD

Department of Laboratory Medicine & Pathology, Center for
Immunology, University of Minnesota, Minneapolis, MN, USA

Benoit Mâsse, PhD

Public Health Sciences Division, Biostatistics, Fred
Hutchinson Cancer Research Center, Seattle, Washington,

USA

Arnaud Moris

INSERM UMR S 945, Infections and Immunity, Avenir Group, Université Pierre et Marie Curie (UPMC), Sorbonne Universités, and Hôpital Pitié-Salpêtrière, Paris, France

Cliff Murray, PhD

Source BioScience, Nottingham, UK

George K. Mutwiri, DVM, PhD

Vaccine & Infectious Disease Organization, Saskatoon; School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada

Scott Napper, PhD

Vaccine & Infectious Disease Organization, Saskatoon; Department of Biochemistry, University of Saskatchewan, Saskatoon, SK, Canada

Derek T. O'Hagan, PhD

Global Head, Vaccine Delivery and Formulation, Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, USA

Yvonne Paterson, PhD

Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA

Andrew A. Potter, PhD, FCAHS

Vaccine & Infectious Disease Organization, Saskatoon; Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK, Canada

Simon J. Powis, PhD

School of Medicine, University of St Andrews, St Andrews,
Fife, UK

Robert Rees

The John van Geest Cancer Research Centre, School of
Science and Technology, Nottingham Trent University,
Nottingham, and CompandX Ltd, Nottingham, UK

Mario Roederer, PhD

Vaccine Research Center, National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health
(NIH), Bethesda, MD, USA

Pedro Romero

Division of Clinical Onco-Immunology, Ludwig Institute for
Cancer Research, Lausanne, Switzerland

Iñaki Sanz, MD

Division of Allergy, Immunology, and Rheumatology,
University of Rochester Medical Center, Rochester, NY, USA

Aaron K. Sato, PhD

OncoMed Pharmaceuticals, Redwood City, CA, USA

John T. Schiller, PhD

Laboratory of Cellular Oncology, National Cancer Institute,
Bethesda, MD, USA

Matthew Seavey, PhD

Department of Microbiology, University of Pennsylvania,
Philadelphia, PA, USA

Robert C. Seid Jr

Intercell USA, Inc., Gaithersburg, MD, USA

Fiona A. Sharp, PhD

Fahmy Research Group, Department of Biomedical Engineering, School of Engineering and Applied Science, Yale University, New Haven, CT, USA

Dmitry Shayakhmetov, PhD

Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA, USA

Michael A. Skinner

Department of Virology, Imperial College London Faculty of Medicine, London, UK

Brian R. Sloat

Pharmaceutics Division, College of Pharmacy, University of Texas-Austin, Austin, USA

Kalathil Suresh, PhD

Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA

Rudolf H. Tangermann, MD

Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland

Yasmin Thanavala, PhD

Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA

Richard W. Titball, BSc, PhD, DSc, FRCPath

School of Biosciences, University of Exeter, Exeter, UK